Personalised medicine: Technological innovation and patient empowerment or exuberant hyperbole?

Drug Discovery World

Volumn 8, Issue 3, 2007, Pages 18-31

  Culbertson, Adam W ^a   Valentine, Stephen J ^b   Naylor, Stephen ^c  

^a INDIANA UNIVERSITY   (United States)

^b Fairbanks Institute   (United States)

^c Beyond Genomics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; TRASTUZUMAB; WARFARIN;

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CONSUMER ATTITUDE; DRUG INDUSTRY; EMPOWERMENT; GENETIC ANALYSIS; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; MEDICAL INFORMATION; MEDICAL TECHNOLOGY; PERSONALIZED MEDICINE; PHARMACEUTICAL CARE; UNSPECIFIED SIDE EFFECT;

EID: 34547609414     PISSN: 14694344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Hippocrates. Encylopaedia Britannica. 2007 Encyclopedia Britannica Online. 25 Apr. (2007) (http://search.eb.com/eb/article-9040540).
2. Yang et al. Cancer Epidemiology Biomarkers & Prevention 16 (3):439-443 Mar (2007).
3. Fraga, MF et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl.Acad. Sci. 102(30): 10413-10414 (2005).
4. Collins, F et al. A vision for the future of genomics research. Nat. 422:835-847 (2003).
5. Center for Disease Control website; (http//www.cdc.gov).
6. Burill & Company. Personalized Medicine are we really ready for this revolution. Oct 18, 2005 slide 20.
7. Hoover Institute. www.hooverinstitute.com (http://www.hoover.org/ research/factsonpolicy/facts/5854746.html).
8. Washington Alliance for a Competitive Economy. November 17, 2006.
9. OEDC Health Database 2006. June 30, 2006. version 6/26/2006.
10. Accenture. The Pursuit of High Performance through Research and Development. Understanding Pharmaceutical Research and Development. accessed from http://www.phrma.org/files/ Accenture%20R&D%20Report-2007.pdf June 17,(2007).
11. Innovation. http://www.innovation.org/index.cfm/InsideDrugDiscovery.
12. Galson, S. FDA. Center for Drug Evaluation and Research (CIDER). Drug Regulation Update. Well-Characterization Biotechnology Products. "WCBP2006" 2006 CDER Update. January, 18 (2007).
13. FDA. Critical Path Initiative: History, Objectives, Approach, June 21 (2005) www.fda.gov/oc/criticalpath/presentations.
14. The Royal Society: Personalised medicines: hopes and realities. 1-50: September, (2005).
15. Personalized Medicine Coalition. The Case for Personalized Medicine. September, (2006).
16. Encyclopaedia Britannica. 2007. Encyclopaedia Britannica Online. http://www.britannica.com/eb/article-216035>. 18 June (2007).
17. Watson, JD and Crick, JHC. A Structure for Deoxyribose Nucleic Acid Nature 171, 737-738 (1953).
18. Biotechnology Hall of Fame. (http://www.chemheritage.org/exhibits/ biotech/boyer.html).
19. Mullis, KB. Target amplification for DNA analysis by the polymerase chain reaction. Ann Biol Clin.; 48(8):579-82 (1990).
20. Human Genome Project. Facts About Genome Sequencing. (http://www.ornl.gov/sci/techresources/Human_Genome/faq/ seqfacts.shtml).
21. Lederberg, J. and McCray, A. 'Ome Sweet' Omics - A Genealogical Treasury of Words. The Scientist 15(7):8 April, 2 (2001).
22. Naylor, S. System Biology, information, disease, and drug discovery. Drug Discovery World. Winter (2004/5).
23. Hood, L. A personal view of molecular technology and how it has changed biology. J. Protome Res. 1:300-409 (2002).
24. Kalyanaraman, A et al. Proceedings. 20th International Parallel and Distributed Processing Symposium 10 (2006).
25. Koeniger, S. An IMS-IMS Analogue of MS-MS. Anal. Chem. 78, 4161-4174 (2006).
26. Collins. Boston Globe. Personalized Medicine a New approach to Staying Well. July 2005. (http://www.boston.com/news/globe/editorial_opinion/ oped/articles/2005/07/17/personalized_medicine/0.
27. Gunter, K and Tarnok, A. Cytomics in Predictive Medicine. Clinical Cytometry 53B: 1-3 (2003).
28. American Board of Preventative Medicine. Booklet of Information. accessed on http://www.abprevmed.org/public/infobook.pdf. Feb. (2007).
29. Sadee, W. Pharmacogenomics: the implementation phase. AAPS PharmSci 4(2): 1-5 (2002).
30. National Center for Biotechnology Information (NCBI).Just the Facts: A Basic Introduction to the Science Underlying NCBI Resources. One Size Does Not Fit All: The Promise of Pharmagenomics. (http://www.ncbi.nlm.nih.gov/About/primer/pharm.html) accessed June, 21 (2007).
31. Human Genome Sequencing Center (HGSC). Baylor College of Medicine. HGSC Glossary. http://www.hgsc.bcm.tmc.edu/docs/HGSC_glossary.html.
32. Mann, RD. From Mithradatium to modern medicine: the management of drug safety. Journal of the Royal Society of Medicine. 81: 725-728 (1988).
33. Drews. J. Drug discovery: a historical perspective. Science. 287(5460): 1960-1964 (2000).
34. Prous, JR, Khurdayan, VK. The Story so far in R&D. Drug News Perspect. 20(1):7-15 (2007).
35. National Cancer Society, Breast Cancer Facts & Figures 2005-2006. http://www.cancer.org/downloads/STT/CAFF2005BrF.pdf.
36. Mendard, S et al. Biologic and therapeutic role of HER2 in cancer. Oncogene. 22(42): 6570-6578 (2003).
37. Piccart-Gebhart, MJ et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Eng J Med; 353; 1659-72.(2005).
38. Herceptin (trastuzmab) (Herceptin; www.herceptin.com).
39. OncotypeDx. (http://www.genomicheaith.com/oncotype/).
40. Rawson, K. The RPM Report. Reimbursing Designer Drugs. Vol. 1, No. 10 Oct. (2006).
41. Palk, S et al. A Multigene Assay to Predict Recurrence of Tamozifen-treated, Node-Neg. Breast Cancer. NEJM. 351(27):2812-2826 (2004).
42. Jabbour et al. Current and Emerging Treatment Options in Chronic Myeloid Leukemia. Cancer; 109:2171-2181 (2007).
43. Genzyme website (http://www.genzyme.com/) http://www.genzymegenetics.com/ testmenu/tests/cancer/geneptestmenucantestBCRABLas accessed May, 30, 2007.
44. Rider, M et al. Effect of VKORCI Haplotypes on Transcriptional Regulation and Warfarin Dose. N Engl J Med. 352;22:2285-2293 (2005).
45. Genelex. http://www.healthanddna.com/professional/pharmacogenetics.html.
46. Appleby, J. USA Today. GAO ounces on home DNA test to predict disease. July, 27 (2006).
47. United States Government Accountability Office. Testimony Before the Special Committee on Again, U.S. Senate. Nutrigenetic Testing. Test Purchased from Four Web Sites Mislead Consumers. GAO-06-977T Thursday, July 27 (2006).
48. Little, Stephen. Personalised Medicine What's in it for big pharma?. Drug Discovery World. Winter: 19-22 (2006).
49. Unknown. Business Week online. http://www.businessweek.com/magazine/ content/04_42/b3904034_mz011.htmlink. October 18, (2004).
50. http://www.cdc.gov/nchs/data/nvsr/nvsr54/nvsr54_19.pdf.